Sort   by:  
 Page size 
GenomicsEffect of CBL0137 on DIPG cells
Effect of CBL0137 on DIPG cells
PRJNA644393 | ENA
GenomicsCombination of CBL0137 and Panobinostat in DIPG
Combination of CBL0137 and Panobinostat in DIPG
PRJNA642726 | ENA
UnknownInitial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Not available
S-EPMC5587189 | biostudies-literature
UnknownCuraxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms.
Not available
S-EPMC6292929 | biostudies-literature
GenomicsTranscriptome analysis of xenograft tumors treated with vehicle control or CBL0137
Transcriptome analysis of xenograft tumors treated with vehicle control or CBL0137
PRJNA590464 | ENA
GenomicsGene expression analysis of Th-MYCN neuroblastoma tumours treated with CBL0137 and panobinostat
Gene expression analysis of Th-MYCN neuroblastoma tumours treated with CBL0137 and panobinostat
PRJNA636966 | ENA
UnknownTargeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo.
Not available
S-EPMC9856019 | biostudies-literature
GenomicsGene expression analysis of a subcutaneous MV4 11 tumor treated with curaxin CBL0137.
Gene expression analysis of a subcutaneous MV4 11 tumor treated with curaxin CBL0137.
PRJNA521944 | ENA
UnknownCuraxin CBL0137 has the potential to reverse HIV-1 latency.
Not available
S-EPMC6599568 | biostudies-literature
TranscriptomicsEffect of CBL0137 on DIPG cells
Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. A high throughput drug screen of 3600 pharmaceutical compounds found that anti-malarials, including quinacrine had potent activity against DIPG neurospheres. CBL0137 is a...
ORGANISM(S): Homo sapiens 
2021-03-07 | GSE153883 | GEO
Sort   by:  
 Page size